Evidence map›Paper›PMID 40146452›Full record

ArticleJournal of patient-reported outcomes2025

Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI.

Claudia Rutherford, Margaret-Ann Tait, Daniel S J Costa, Madeleine T King, David P Smith, Shomik Sengupta, Joseph Ischia, Andrew Mitterdorfer, Dickon Hayne, Roger Watson and 14 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Claudia RutherfordFaculty of Medicine and Health, Susan Wakil School of Nursing and Midwifery, University of Sydney, Sydney, Australia. claudia.rutherford@sydney.edu.au.ORCID http://orcid.org/0000-0002-4637-4572
Margaret-Ann TaitFaculty of Medicine and Health, Susan Wakil School of Nursing and Midwifery, University of Sydney, Sydney, Australia.
Daniel S J CostaFaculty of Science, School of Psychology, University of Sydney, Sydney, NSW, Australia.
Madeleine T KingFaculty of Science, School of Psychology, University of Sydney, Sydney, NSW, Australia.
David P SmithThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council New South Wales, Sydney, NSW, Australia.
Shomik SenguptaEastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
Joseph IschiaDepartment of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.
Andrew MitterdorferConcord Repatriation General Hospital, Concord, NSW, Australia.
Dickon HayneANZUP Cancer Trials Group, Sydney, NSW, Australia.
Roger WatsonANZUP Cancer Trials Group, Sydney, NSW, Australia.
Paul AndersonANZUP Cancer Trials Group, Sydney, NSW, Australia.
Mark FrydenbergMonash Medical Centre, Department of Surgery, Monash University, Melbourne, VIC, Australia.
Peter GillingTauranga Urology Research, Tauranga, New Zealand.
Nicholas BuchanANZUP Cancer Trials Group, Sydney, NSW, Australia.
Euan GreenThe Christie and Salford Royal Hospitals, Manchester, UK.
Noel ClarkeThe Christie and Salford Royal Hospitals, Manchester, UK.
Stephen A BoorjianMayo Clinic, Rochester, MN, USA.
Badrinath KonetyUniversity of Minnesota, Minneapolis, MN, USA.
Jeffrey M HolzbeierleinUniversity of Kansas Health System, Kansas City, KS, USA.
Peter C BlackUniversity of British Columbia, Vancouver, BC, Canada.
Venu ChalasaniANZUP Cancer Trials Group, Sydney, NSW, Australia.
Jörg HenselerUniversity of Twente, Enschede, The Netherlands.
Manish I PatelANZUP Cancer Trials Group, Sydney, NSW, Australia.
NMIBC-SI Study Group

Funding

Cancer Council NSW and Cancer Australia 1103036
6 · The paper itself

Abstract

BACKGROUND AND

objectiveNon-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring frequent follow-up with endoscopic examinations, tumour resections and intravesical treatments. In this clinical context, patient-reported outcomes (PROs) have enormous potential to inform treatment assessment and recommendations for NMIBC. We aimed to develop and evaluate a patient-reported NMIBC Symptom Index (NMIBC-SI) to facilitate clinical research and enhance care.

methodsNMIBC-SI items were developed based on existing literature and qualitative interviews with patients and clinicians, and evaluated in two field tests: item reduction, using NMIBC-SI data from 220 patients on active treatment from nine Australian centres; reliability and validity evaluation of item-reduced version using NMIBC-SI data from 232 patients from five countries.

resultsNMIBC-SI assesses disease and treatment-related symptom burden and two treatment-specific side-effects (cystoscopy, intravesical BCG/Chemotherapy). Composite analysis supported a single composite model including core symptom and cystoscopy index items (Intravesical index items were not tested due to small sample). Test-retest reliability was strong (range 0.894-0.91). As expected, the NMIBC-SI was able to discriminate between no treatment and any treatment groups, and no treatment and chemo/BCG groups, providing evidence towards validity. CONCLUSIONS AND CLINICAL IMPLICATIONS: NMIBC-SI assesses patients' self-reported symptom burden and can be used to evaluate NMIBC treatments from the perspective of patients. The NMIBC-SI is acceptable to patients and has evidence for reliability and validity. Future validation work with patients with greater symptom burden is warranted.

Indexed as

Patient Reported Outcome MeasuresUrinary Bladder NeoplasmsAdultAgedAged, 80 and overAustraliaBCG VaccineCystoscopyFemaleHumansMaleMiddle AgedNon-Muscle Invasive Bladder NeoplasmsPsychometricsReproducibility of ResultsSurveys and QuestionnairesBCG VaccineEarly bladder cancerMeasurement propertiesNon-muscle invasive bladder cancerPatient-reported outcomePatient-reported outcome measureSymptom benefitSymptom burdenSymptom index

Identifiers

PMID40146452
PMCPMC11950540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.